Bluebird Bio appoints Alexandre LeBeaut as chief medical officer
This article was originally published in Scrip
Executive Summary
Bluebird Bio, a privately held company focused on the development of gene therapies for severe genetic disorders, has appointed Dr Alexandre LeBeaut chief scientific officer. Dr LeBeaut has more than 20 years' of industry experience, having most recently served as chief scientific officer at Axcan Pharma. Dr LeBeaut has also previously worked in clinical positions at Sanofi-Aventis Pharmaceuticals, Novartis Pharmaceuticals and Schering-Plough. Bluebird is backed by life sciences investors, including Third Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital and Genzyme Ventures.